ArticleCancer management and research2025
Prognostic Significance of Cervical Lymph Node Biopsy in Nasopharyngeal Carcinoma Patients: A Retrospective Analysis.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The impact of cervical lymph node biopsy on survival, distant metastasis, and local recurrence in nasopharyngeal carcinoma (NPC) patients remains controversial. This study aims to compare the effects of cervical lymph node biopsy and nasopharyngeal biopsy on these outcomes. Methods: This retrospective study enrolled NPC patients treated at the First Affiliated Hospital of Soochow University between January 2013 and December 2021. Kaplan-Meier method was used to evaluate the overall survival (OS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRFS), nodal recurrence-free survival (NRFS), and progression-free survival (PFS), with comparisons using the Log rank test. Univariate and multivariate Cox regression models were used to identify independent prognostic factors. Results: A total of 721 NPC patients who underwent radiotherapy were retrospectively analyzed. Among them, 591 were diagnosed with nasopharyngeal biopsy, and 130 patients with cervical lymph node metastasis suspected to originate from NPC underwent confirmatory nasopharyngeal biopsy. In cervical lymph node biopsy, 36 had excisional biopsies, 85 had fine needle aspirations, and 9 cases were unspecified. Survival was not significantly different between patients with nasopharyngeal biopsy and cervical lymph node biopsy (5-year OS: 81.1% vs 85.0%; DMFS: 75.2% vs 80.6%; LRFS: 79.5% vs 78.7%; NRFS: 80.4% vs 80.4%; PFS: 74.3% vs 74.3%; all p>0.05). Results were similar for the propensity-matched cohort of 260 patients.Additionally, survival was not significantly different between the fine needle aspiration and excision biopsy groups (5-year OS: 85.1% vs 83.5%; DMFS: 79.7% vs 80.3%; LRFS: 85.2% vs 74.8%; NRFS: 85.1% vs 77.7%; PFS: 79.8% vs 71.7%; all p>0.05). Targeted therapy and >3 cycles of chemotherapy were prognostic factors in NPC patients (p<0.05). Conclusion: Cervical lymph node biopsy did not increase the risk of locoregional recurrence, distant metastasis, or death in NPC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.